Abstract
The clinical efficacy of ara-C is limited by a rapid elimination of the active triphosphate by target cells. The nucleoside antimetabolite, 2',2'-difluorodeoxycytidine, accumulates in leukemia cells as the respective 5'-triphosphate dFdCTP. In contrast to ara-C triphosphate, dFdCTP is eliminated with biphasic kinetics that exhibit a terminal half-life that approaches the cell cycle time. The cellular pharmacokinetics of dFdCTP may explain the unusual dose schedule and spectrum of efficacy against murine tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 77-79 |
| Number of pages | 3 |
| Journal | Nucleic acids symposium series |
| Issue number | 18 |
| State | Published - 1987 |
ASJC Scopus subject areas
- General Medicine